Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Janux Therapeutics (JANX) Long-Term Debt Issuances: 2020-2021

  • Janux Therapeutics' Long-Term Debt Issuances was N/A to $68.8 million in Q2 2021 from the same period last year, while for Jun 2021 it was $129.3 million, marking a year-over-year change of. This contributed to the annual value of $124.8 million for FY2021, which is 1294.07% up from last year.
  • Per Janux Therapeutics' latest filing, its Long-Term Debt Issuances stood at $68.8 million for Q2 2021, which was up 22.90% from $56.0 million recorded in Q1 2021.
  • In the past 5 years, Janux Therapeutics' Long-Term Debt Issuances registered a high of $68.8 million during Q2 2021, and its lowest value of -$33,000 during Q3 2020.
  • Moreover, its 2-year median value for Long-Term Debt Issuances was $30.2 million (2020), whereas its average is $32.3 million.